Navigation Links
Colon cancer patients benefit from Hepatic Arterial Infusion Therapy

A new study conducted by Nancy E. Kemeny, MD, an Attending Physician in the Department of Medicine at Memorial Sloan-Kettering Cancer Center// said that patients whose colorectal cancer has spread to the liver fared better by receiving hepatic arterial infusion (HAI). In this technique chemotherapy was administered directly to the liver through a pump in the abdomen. It was found that the patients on the HAI therapy lived longer and had better quality of life than those receiving the traditional, intravenous chemotherapy. The results of the study were published in the Journal of Clinical Oncology.

This study demonstrated the effectiveness of the hepatic arterial infusion therapy. It showed that it extended the survival and improved the quality of life in patients with colorectal cancer that has spread to the liver. These findings are very important because statistics show that cancer metastasis to the liver occurs in 60 % of patients with metastatic colorectal cancer. This discovery will also reduce the number of deaths due to liver tumors.

The study was conducted by researchers from the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. The participants consisted of 135 patients who received either HAI or systemic chemotherapy. Prior to this all of the patients are needed to undergo surgical removal of their primary tumors in the colon. In case of patients receiving HAI then underwent an additional surgical procedure to have chemotherapy pump inserted into their abdomen.

Researchers found that patients receiving HAI lived longer (median survival rate of 24 months) than those receiving systemic chemotherapy. They also had better response rates (47 %) and longer time to disease progression in the liver (9.8 months).

On the other hand patients receiving systemic chemotherapy experienced various side effects such as diarrhea, decreased white blood cell counts, and hair loss. However, patients on the HAI regimen experienced mild toxicity to the liver.

In case of both the regimes women fared better than men, with median survival in the HAI group of 29.4 and 20.1 months for women and men, respectively, and in the systemic group it was 22.0 and 18.3 months.

This research was initiated in the year 1996, before the novel chemotherapy drugs such as irinotecan and oxaliplatin were available. In the study the patients received fluorouracil and leucovorin. Dr. Kemeny said that future studies are underway using HAI therapy in combination with newer drugs.


'"/>




Related medicine news :

1. Cancers of Colon & Rectum linked to Cigarette Smoking
2. Need for Colon cancer screening
3. Beer guards against Colon Cancer
4. Important substance in curry conciliate Inflamed Colon
5. Colon cancer linked with common virus
6. Colon cancer risk linked to genes causing Hemochromatosis
7. Death Risk Higher in Obese Women with Colon Cancer
8. Inflammation Linked to Colon Cancer
9. Aspirin Found To Reduce The Risk Of Colon Cancer
10. Blood Marker Found To Predict Colon Cancer
11. Estrogen Found To Protect the Colon Against Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: